CA2229405A1 - Methods for enhancing the production of interferon in cell culture - Google Patents
Methods for enhancing the production of interferon in cell cultureInfo
- Publication number
- CA2229405A1 CA2229405A1 CA002229405A CA2229405A CA2229405A1 CA 2229405 A1 CA2229405 A1 CA 2229405A1 CA 002229405 A CA002229405 A CA 002229405A CA 2229405 A CA2229405 A CA 2229405A CA 2229405 A1 CA2229405 A1 CA 2229405A1
- Authority
- CA
- Canada
- Prior art keywords
- interferon
- production
- methods
- enhancing
- cell culture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/18—Testing for antimicrobial activity of a material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32051—Methods of production or purification of viral material
Abstract
Methods for enhancing the production of interferons in animal cell culture are described. These methods rely on the manipulation of the cellular levels of certain inducers of interferon production, in particular cellular levels of double-stranded-RNA-dependent kinase (dsRNA-PKR, or PKR). In cell cultures that overproduce PKR, interferon synthesis is induced to high levels, and significant amount of interferon can be recovered without conventional induction of interferon by virus.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US262195P | 1995-08-22 | 1995-08-22 | |
US60/002,621 | 1995-08-22 | ||
PCT/US1996/013627 WO1997008324A1 (en) | 1995-08-22 | 1996-08-22 | Methods for enhancing the production of interferon in cell culture |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2229405A1 true CA2229405A1 (en) | 1997-03-06 |
CA2229405C CA2229405C (en) | 2004-03-02 |
Family
ID=21701659
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2229163A Expired - Lifetime CA2229163C (en) | 1995-08-22 | 1996-08-22 | Methods for enhancing the production of viral vaccines in cell culture by interferon suppression |
CA002229405A Expired - Fee Related CA2229405C (en) | 1995-08-22 | 1996-08-22 | Methods for enhancing the production of interferon in cell culture |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2229163A Expired - Lifetime CA2229163C (en) | 1995-08-22 | 1996-08-22 | Methods for enhancing the production of viral vaccines in cell culture by interferon suppression |
Country Status (10)
Country | Link |
---|---|
US (6) | US5840565A (en) |
EP (2) | EP0846160B1 (en) |
JP (2) | JP4267693B2 (en) |
CN (1) | CN1161469C (en) |
AT (1) | ATE289348T1 (en) |
AU (2) | AU6857696A (en) |
BR (1) | BR9610550A (en) |
CA (2) | CA2229163C (en) |
DE (1) | DE69634360T2 (en) |
WO (2) | WO1997008292A1 (en) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6855519B2 (en) * | 1995-08-22 | 2005-02-15 | The Regents Of The University Of California | Methods for enhancing the production of interferon in cell culture |
US5840565A (en) * | 1995-08-22 | 1998-11-24 | The Regents Of The University Of California | Methods for enhancing the production of viral vaccines in PKR-deficient cell culture |
US6740519B1 (en) | 1997-11-03 | 2004-05-25 | Mount Sinai School Of Medicine | Immortalized, homozygous stat1-deficient mammalian cell lines and their uses |
EP1085904B1 (en) * | 1998-06-12 | 2012-11-28 | Mount Sinai School of Medicine | Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals |
US6762038B1 (en) | 1998-09-09 | 2004-07-13 | The Cleveland Clinic Foundation | Mutant cell lines and methods for producing enhanced levels of recombinant proteins |
CN1399681A (en) * | 1999-06-15 | 2003-02-26 | 基因特罗生物治疗公司 | Methods for enhancing the production of cytokines in cell culture |
EP1067179A1 (en) * | 1999-07-09 | 2001-01-10 | Pierre Fabre Medicament | Method to select attenuated paramyxoviridae useful for vaccines and therapeutics |
JP2003509025A (en) * | 1999-09-08 | 2003-03-11 | ジーントロール バイオセラピューティクス, インコーポレイテッド | High level cytokine production with enhanced cell viability |
US20010031859A1 (en) * | 1999-09-08 | 2001-10-18 | Lau Allan S. | High level cytokine production with enhanced cell viability |
US6635416B2 (en) | 2000-04-10 | 2003-10-21 | Mount Sinai School Of Medicine Of New York University | Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents |
IL136232A0 (en) * | 2000-05-18 | 2001-05-20 | Bar Ilan University Res Author | Measurements of enzymatic activity in a single, individual cell in population |
EP1320583B1 (en) * | 2000-08-04 | 2006-03-01 | Chiron Corporation | Enhanced replication of hcv rna |
US20020150541A1 (en) * | 2000-09-12 | 2002-10-17 | Gene Trol Biotherapeutics, Inc. | Compositions comprising mixtures of therapeutic proteins and methods of producing the same |
US6864061B2 (en) | 2000-09-14 | 2005-03-08 | Genetrol Biotherapeutics, Inc. | Method for screening compounds for anti-inflammatory activity |
WO2002062837A2 (en) * | 2000-12-19 | 2002-08-15 | Genetrol Biotherapeutics, Inc. | Cells with enhanced pkr expression for increasing cytokine production |
DE10104094C1 (en) * | 2001-01-31 | 2002-07-25 | Angelika Vallbracht-Flehmig | Increasing viral replication and yield in cell cultures, useful e.g. for detecting residual hepatitis A in inactivated products, by blocking activation of RNaseL |
WO2003035824A1 (en) * | 2001-10-25 | 2003-05-01 | Bar-Ilan University | Interactive transparent individual cells biochip processor |
IL154677A0 (en) | 2003-02-27 | 2003-09-17 | Univ Bar Ilan | A method and apparatus for manipulating an individual cell |
US8597597B2 (en) | 2003-06-26 | 2013-12-03 | Seng Enterprises Ltd. | Picoliter well holding device and method of making the same |
US20060240548A1 (en) * | 2003-06-26 | 2006-10-26 | Mordechai Deutsch | Materials for constructing cell-chips, cell-chip covers, cell-chips coats, processed cell-chips and uses thereof |
US9200245B2 (en) | 2003-06-26 | 2015-12-01 | Seng Enterprises Ltd. | Multiwell plate |
US7888110B2 (en) | 2003-06-26 | 2011-02-15 | Seng Enterprises Ltd. | Pico liter well holding device and method of making the same |
US7982751B2 (en) * | 2003-07-11 | 2011-07-19 | The University Of North Carolina | Methods and systems for controlling a computer using a video image and for combining the video image with a computer desktop |
US20050064524A1 (en) * | 2003-08-11 | 2005-03-24 | Mordechai Deutsch | Population of cells utilizable for substance detection and methods and devices using same |
CN103446582A (en) * | 2003-08-11 | 2013-12-18 | 财团法人阪大微生物病研究会 | Novel vaccine containing adjuvant capable of inducing mucosal immunity |
NZ603105A (en) * | 2003-10-23 | 2014-08-29 | Kineta Two Llc | Detection of mutations in a gene associated with resistance to viral infection, oasi |
EP2083089A1 (en) | 2003-10-23 | 2009-07-29 | Illumigen Biosciences, Inc. | Detection of mutations in a gene associated with resistance to viral infection, oas1 |
WO2005074524A2 (en) | 2004-02-02 | 2005-08-18 | Ambrx, Inc. | Modified human interferon polypeptides and their uses |
BRPI0506610A (en) * | 2004-02-03 | 2007-05-02 | Chemagis Ltd | amorphous montelukast sodium, amorphous sodium montelukast preparation process, pharmaceutical composition, treatment method using the administration of amorphous montelukast sodium, amorphous montelukast amorphous co-precipitate and amorphous montelukast amorphous co-precipitate preparation process |
DE602005015332D1 (en) * | 2004-02-23 | 2009-08-20 | Crucell Holland Bv | Method for cleaning viruses |
EP2497492B1 (en) | 2004-06-01 | 2018-08-08 | Icahn School of Medicine at Mount Sinai | Genetically engineered swine influenza virus and uses thereof |
US20080063251A1 (en) * | 2004-07-07 | 2008-03-13 | Mordechai Deutsch | Method and Device for Identifying an Image of a Well in an Image of a Well-Bearing |
US7403647B2 (en) * | 2004-09-13 | 2008-07-22 | Seng Enterprises Ltd. | Method for identifying an image of a well in an image of a well-bearing component |
US20080009051A1 (en) * | 2004-08-25 | 2008-01-10 | Seng Enterprises Ltd. | Method and Device for Isolating Cells |
US20060051369A1 (en) * | 2004-08-27 | 2006-03-09 | Taylor Deborah R | ADAR1 antiviral pathway |
US20080107683A1 (en) * | 2004-11-30 | 2008-05-08 | David Hone | Bacterial Packaging Strains Useful for Generation and Production of Recombinant Double-Stranded RNA Nucleocapsids and Uses Thereof |
ES2352344T3 (en) | 2005-01-25 | 2011-02-17 | Seng Enterprises Limited | MICROFLUID DEVICE FOR CELL STUDY. |
US8137676B2 (en) | 2005-02-15 | 2012-03-20 | Mount Sinai School Of Medicine | Genetically engineered equine influenza virus and uses thereof |
WO2006108707A1 (en) * | 2005-04-11 | 2006-10-19 | Crucell Holland B.V. | Virus purification using ultrafiltration |
UA95446C2 (en) * | 2005-05-04 | 2011-08-10 | Іллюміджен Байосайєнсіз, Інк. | Mutations in oas1 genes |
DE102005034043B4 (en) * | 2005-07-18 | 2019-12-12 | Südzucker Aktiengesellschaft Mannheim/Ochsenfurt | Mixture containing L-carnitine and trehalulose and product containing the mixture |
US20070111309A1 (en) * | 2005-10-04 | 2007-05-17 | Daelli Marcelo G | Vero cell line adapted to grow in suspension |
US20070141555A1 (en) * | 2005-10-11 | 2007-06-21 | Mordechai Deutsch | Current damper for the study of cells |
WO2007052245A1 (en) | 2005-11-03 | 2007-05-10 | Seng Enterprises Ltd. | Method and device for studying floating, living cells |
US20070196333A1 (en) * | 2006-02-23 | 2007-08-23 | Fu-Yung Lin | Composition comprising mixtures of IFN-alpha subtypes |
US20060223999A1 (en) * | 2006-05-10 | 2006-10-05 | Chemagis Ltd. | Process for preparing montelukast and precursors thereof |
AU2008247815B2 (en) | 2007-05-02 | 2012-09-06 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
US9145540B1 (en) | 2007-11-15 | 2015-09-29 | Seng Enterprises Ltd. | Device for the study of living cells |
EP2237887A2 (en) | 2007-12-26 | 2010-10-13 | Seng Enterprises Ltd. | Device for the study of living cells |
NZ620606A (en) | 2008-02-08 | 2015-08-28 | Ambrx Inc | Modified leptin polypeptides and their uses |
EP2133358A1 (en) * | 2008-06-10 | 2009-12-16 | Universitätsklinikum Freiburg | Rift valley fever virus-like particles and their use for immunization and as test system |
KR101707569B1 (en) | 2008-08-01 | 2017-02-16 | 감마 백신즈 피티와이 리미티드 | Influenza vaccines |
US9884105B2 (en) * | 2008-12-16 | 2018-02-06 | Ology Bioservices, Inc. | Production of viral vaccine |
JP2013523175A (en) | 2010-04-14 | 2013-06-17 | イーエムディー・ミリポア・コーポレーション | Method for producing high-titer and high-purity virus stock and method for using the same |
EP2667891B1 (en) | 2011-01-27 | 2021-10-06 | Gamma Vaccines Pty Limited | Combination vaccines |
EP2855701A1 (en) * | 2012-06-04 | 2015-04-08 | Novartis AG | Improved safety testing |
EP2954055B1 (en) * | 2013-02-05 | 2018-04-11 | University of Georgia Research Foundation, Inc. | Cell lines for virus production and methods of use |
EA201791907A1 (en) | 2015-02-26 | 2018-02-28 | Бёрингер Ингельхайм Ветмедика Гмбх | BIVALENT VACCINE AGAINST SWINE FLU VIRUS |
WO2017070167A1 (en) * | 2015-10-20 | 2017-04-27 | The University Of North Carolina At Chapel Hill | Methods and compositions for modified factor ix fusion proteins |
KR102651055B1 (en) | 2016-03-24 | 2024-03-26 | 삼성디스플레이 주식회사 | Optical film and display apparatus |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE33164E (en) * | 1979-05-15 | 1990-02-13 | Mobay Corporation | Influenza vaccine production in liquid cell culture |
JPS5754586A (en) * | 1980-09-18 | 1982-04-01 | Ajinomoto Co Inc | Cell strain producing human interferon prolongably, its preparation, and preparation of human interferon using it |
US4579821A (en) * | 1981-11-23 | 1986-04-01 | University Patents, Inc. | Control of DNA sequence transcription |
JPS58209993A (en) * | 1982-05-31 | 1983-12-07 | Mochida Pharmaceut Co Ltd | Production of interferon |
JPH0636751B2 (en) * | 1982-06-21 | 1994-05-18 | ザ・ウエルカム・フアウンデ−シヨン・リミテツド | Improved manufacturing method of interferon |
US4485038A (en) * | 1982-10-19 | 1984-11-27 | Health Research (Roswell Park Division) | Method for the production and purification of human leukocyte interferon |
US4966843A (en) * | 1982-11-01 | 1990-10-30 | Cetus Corporation | Expression of interferon genes in Chinese hamster ovary cells |
US4745053A (en) * | 1983-07-08 | 1988-05-17 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyojo | Process for producing human interferon and method for assaying the interferon productivity of blood |
JPS6062997A (en) * | 1983-09-17 | 1985-04-11 | Mochida Pharmaceut Co Ltd | Preparation of interferon |
US5196323A (en) * | 1985-04-27 | 1993-03-23 | Boehringer Ingelheim International Gmbh | Process for preparing and purifying alpha-interferon |
US4732683A (en) * | 1986-12-02 | 1988-03-22 | Biospectrum, Inc. | Purification method for alpha interferon |
ES2110411T3 (en) * | 1989-08-25 | 1998-02-16 | Chiron Corp | METHODS FOR CULTIVATING HEPATITIS C VIRUS (HCV) IN CELL LINES OF LYMPHOCYTES B OR T. |
US5149531A (en) * | 1990-06-27 | 1992-09-22 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Method of using cold-adapted live influenza virus vaccine as an antiviral agent against influenza |
JPH05260981A (en) * | 1992-03-02 | 1993-10-12 | Massachusetts Inst Of Technol <Mit> | Dna encoding eukaryotic initiation factor 2 alpha kinase regulated with hem |
FR2689520B1 (en) * | 1992-04-03 | 1996-07-19 | Bio Merieux | METHOD AND CULTURE MEDIUM FOR OBTAINING CELLS INFECTED WITH A VIRUS ASSOCIATED WITH MULTIPLE SCLEROSIS. |
US5840565A (en) * | 1995-08-22 | 1998-11-24 | The Regents Of The University Of California | Methods for enhancing the production of viral vaccines in PKR-deficient cell culture |
-
1996
- 1996-08-21 US US08/700,198 patent/US5840565A/en not_active Expired - Lifetime
- 1996-08-22 AU AU68576/96A patent/AU6857696A/en not_active Abandoned
- 1996-08-22 CA CA2229163A patent/CA2229163C/en not_active Expired - Lifetime
- 1996-08-22 WO PCT/US1996/013745 patent/WO1997008292A1/en active IP Right Grant
- 1996-08-22 AU AU68608/96A patent/AU707130B2/en not_active Expired
- 1996-08-22 BR BR9610550A patent/BR9610550A/en not_active Application Discontinuation
- 1996-08-22 EP EP96929066A patent/EP0846160B1/en not_active Expired - Lifetime
- 1996-08-22 DE DE69634360T patent/DE69634360T2/en not_active Expired - Lifetime
- 1996-08-22 CN CNB961977515A patent/CN1161469C/en not_active Expired - Fee Related
- 1996-08-22 JP JP51050897A patent/JP4267693B2/en not_active Expired - Lifetime
- 1996-08-22 WO PCT/US1996/013627 patent/WO1997008324A1/en not_active Application Discontinuation
- 1996-08-22 EP EP96929017A patent/EP0846174A4/en not_active Withdrawn
- 1996-08-22 JP JP51045097A patent/JP3432519B2/en not_active Expired - Fee Related
- 1996-08-22 AT AT96929066T patent/ATE289348T1/en active
- 1996-08-22 CA CA002229405A patent/CA2229405C/en not_active Expired - Fee Related
-
1999
- 1999-11-19 US US09/444,224 patent/US6159712A/en not_active Expired - Fee Related
-
2000
- 2000-06-12 US US09/591,813 patent/US6489144B1/en not_active Expired - Fee Related
- 2000-12-13 US US09/736,748 patent/US6673591B2/en not_active Expired - Fee Related
- 2000-12-13 US US09/737,126 patent/US6686190B2/en not_active Expired - Lifetime
-
2003
- 2003-11-24 US US10/722,349 patent/US7132271B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP0846174A4 (en) | 2003-02-05 |
US20040157310A1 (en) | 2004-08-12 |
CA2229405C (en) | 2004-03-02 |
AU707130B2 (en) | 1999-07-01 |
JP4267693B2 (en) | 2009-05-27 |
BR9610550A (en) | 1999-07-06 |
CA2229163A1 (en) | 1997-03-06 |
US5840565A (en) | 1998-11-24 |
MX9801423A (en) | 1998-05-31 |
DE69634360D1 (en) | 2005-03-24 |
WO1997008292A1 (en) | 1997-03-06 |
CN1200148A (en) | 1998-11-25 |
US6489144B1 (en) | 2002-12-03 |
AU6860896A (en) | 1997-03-19 |
US7132271B2 (en) | 2006-11-07 |
US6686190B2 (en) | 2004-02-03 |
DE69634360T2 (en) | 2005-12-29 |
US20010001709A1 (en) | 2001-05-24 |
US20010001290A1 (en) | 2001-05-17 |
CN1161469C (en) | 2004-08-11 |
EP0846160A1 (en) | 1998-06-10 |
CA2229163C (en) | 2011-04-05 |
JPH11514344A (en) | 1999-12-07 |
EP0846174A1 (en) | 1998-06-10 |
EP0846160A4 (en) | 2002-01-02 |
JPH11511324A (en) | 1999-10-05 |
AU6857696A (en) | 1997-03-19 |
JP3432519B2 (en) | 2003-08-04 |
WO1997008324A1 (en) | 1997-03-06 |
US6673591B2 (en) | 2004-01-06 |
ATE289348T1 (en) | 2005-03-15 |
US6159712A (en) | 2000-12-12 |
EP0846160B1 (en) | 2005-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2229405A1 (en) | Methods for enhancing the production of interferon in cell culture | |
HU9201712D0 (en) | A mammalian cytokine, il-11 | |
PT82127A (en) | Process for the preparation of phenyl carbamates | |
ZA925735B (en) | Stable recombinant yeasts useful for the production of recombinant proteins,their preparation and their use | |
NZ315357A (en) | Method for industrially producing a japanese encephalitis vaccine, and resulting vaccine | |
DE68903576D1 (en) | SIGNAL PEPTIDES EFFECTIVE IN YEAST AND THEIR USE FOR THE SECRETORIC EXPRESSION OF HETEROLOGICAL PROTEINS. | |
AU621810B2 (en) | Amylolytic enzymes producing microorganisms, constructed by recombinant DNA technology and their use for fermentation processes | |
CA2031354A1 (en) | Method of stabilizing recombinant hepatitis b virus surface proteins from yeast | |
EP0094317A3 (en) | Production of interleukin and its analogous immune regulating factors | |
DK128387D0 (en) | PEPTIDE. | |
ATE366803T1 (en) | HIGH CYTOKINE PRODUCTION WITH IMPROVED CELL VIABILITY | |
EP0299354A3 (en) | Monoclonal antibodies against protein e7 of the human papilloma virus type 16, their production process and their use | |
NZ333412A (en) | Plant proteins treated to reduce isoflavones, manganese and nucleotides and nutritional products made therefrom | |
CA2040001A1 (en) | Hypoallergenic wheat preparation, process for producing the same, and processed food including the same | |
DE3279949D1 (en) | Novel microorganisms of the genus eschericia, hybrid dna for use in their production and the use of the microorganisms in the preparation of glutathione | |
JPS5518449A (en) | Increasing method of phycocyanin yield | |
AU4075093A (en) | Cellular aggregate stabilized culture and process for the development of embryos from a proembryogenic strain for use in vine regeneration techniques | |
JPS5668388A (en) | Production of cell body of spirulina algae | |
JPS5585390A (en) | Promotion of proliferation of bifidobacterium | |
Oner | Estimation of growth yields in aerobic and anaerobic cultures | |
WO2002062837A3 (en) | Cells with enhanced pkr expression for increasing cytokine production | |
UA9690A (en) | Inducer of interferon type i in cell cultures | |
Doherty | Toward. And Away From. An Aesthetic of Popular Culture | |
KR900018384A (en) | Antibiotic aranosine, its microbiological preparation and its use as a medicament | |
AU1822195A (en) | Process to "in vitro" propagate the hepatitis c virus (hcv) in non lymphoblastoid animal cell cultures and products thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |